Business Context and Reporting Period
Company: GlaxoSmithKline plc (GSK)
Filing Type: Form 6-K (Report of Foreign Private Issuer)
Date: August 21, 2019
Subject: Submission of a Japanese New Drug Application (JNDA) for daprodustat to treat renal anaemia due to chronic kidney disease (CKD).
Key Financial Metrics
This filing is a regulatory update regarding clinical development and does not contain financial statements. The filing text does not provide clear values for revenue, profit, cash flow, margins, debt, or liquidity.
Material Changes
The primary material event is the first regulatory submission for daprodustat in Japan. This follows a strategic commercialisation deal announced in 2018 with Kyowa Kirin Co., Ltd., which will exclusively distribute the drug in Japan if approved.
Guidance, Outlook, and Risks
- Regulatory Outlook: GSK seeks marketing approval for daprodustat, an oral hypoxia-inducible factor prolyl hydroxylase inhibitor (HIF-PHI), for patients with renal anaemia across CKD stages 3-5 (both dialysis and non-dialysis).
- Clinical Data Basis: The JNDA is based on positive data from three Phase 3 studies in Japan involving 598 patients total (271 haemodialysis, 299 non-dialysis, and 28 open-label haemodialysis).
- Global Pipeline: GSK is conducting global Phase 3 registration programmes:
- ASCEND-D: ~3,000 dialysis-dependent patients; recruitment completed.
- ASCEND-ND: ~4,500 non-dialysis-dependent patients; recruitment ongoing.
- Market Context: Approximately 3.5 million patients in Japan have anaemia associated with renal disease. Daprodustat aims to offer an oral alternative to injectable erythropoiesis-stimulating agents (ESAs).
- Risks: Daprodustat is not currently approved anywhere in the world. Forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially from projections.
Investor Verification Checklist
- Verify the approval status of the JNDA with the Japanese Ministry of Health, Labour and Welfare.
- Monitor the results of the global Phase 3 studies (ASCEND-D and ASCEND-ND), specifically regarding non-inferiority on major adverse cardiovascular events (MACE) and haemoglobin changes.
- Review the commercialisation agreement terms with Kyowa Kirin Co., Ltd. for revenue sharing or milestone payments.
- Assess the competitive landscape for oral HIF-PHIs versus existing injectable ESA treatments.